Primecap Management’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.46M | Buy |
5,719,140
+787,300
| +16% | +$890K | 0.01% | 277 |
|
|
2025
Q1 | $7.2M | Buy |
4,931,840
+4,500
| +0.1% | +$6.57K | 0.01% | 267 |
|
|
2024
Q4 | $10.5M | Sell |
4,927,340
-740,920
| -13% | -$1.58M | 0.01% | 254 |
|
|
2024
Q3 | $15.9M | Sell |
5,668,260
-1,966
| -0% | -$5.51K | 0.01% | 247 |
|
|
2024
Q2 | $13.2M | Buy |
5,670,226
+221,840
| +4% | +$517K | 0.01% | 249 |
|
|
2024
Q1 | $24.4M | Buy |
5,448,386
+166,500
| +3% | +$744K | 0.02% | 222 |
|
|
2023
Q4 | $17M | Sell |
5,281,886
-2,500
| -0% | -$8.03K | 0.01% | 237 |
|
|
2023
Q3 | $16.8M | Sell |
5,284,386
-352,300
| -6% | -$1.12M | 0.01% | 238 |
|
|
2023
Q2 | $28M | Sell |
5,636,686
-132,300
| -2% | -$658K | 0.02% | 216 |
|
|
2023
Q1 | $28.5M | Buy |
5,768,986
+825,070
| +17% | +$4.08M | 0.02% | 208 |
|
|
2022
Q4 | $31.1M | Buy |
4,943,916
+51,050
| +1% | +$321K | 0.03% | 192 |
|
|
2022
Q3 | $52.8M | Buy |
4,892,866
+9,900
| +0.2% | +$107K | 0.05% | 169 |
|
|
2022
Q2 | $55.7M | Sell |
4,882,966
-23,300
| -0.5% | -$266K | 0.05% | 171 |
|
|
2022
Q1 | $44.7M | Buy |
4,906,266
+244,451
| +5% | +$2.23M | 0.03% | 198 |
|
|
2021
Q4 | $69.6M | Buy |
4,661,815
+1,057,515
| +29% | +$15.8M | 0.05% | 175 |
|
|
2021
Q3 | $92.6M | Buy |
3,604,300
+27,270
| +0.8% | +$701K | 0.07% | 158 |
|
|
2021
Q2 | $93.3M | Buy |
3,577,030
+2,271,630
| +174% | +$59.2M | 0.06% | 157 |
|
|
2021
Q1 | $46.1M | Buy |
1,305,400
+67,000
| +5% | +$2.37M | 0.03% | 198 |
|
|
2020
Q4 | $31.3M | Buy |
+1,238,400
| New | +$31.3M | 0.02% | 210 |
|